Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04055870 · ClinicalTrials.gov registry record
Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 24
- Enrollment target
NCT04055870: Completed study, sponsored by Methodist Health System.
NCT04055870 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04055870 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC).
Interventions
- PROCEDURE EUS-guided liver biopsy at MDMC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2020-10-30 |
What the finished NCT04055870 record still lists
NCT04055870 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which EUS-guided liver biopsy at MDMC is the first listed.
NCT04055870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04055870 about?
NCT04055870 is a clinical study titled "Efficacy, Safety, and Adequacy of EUS-guided Liver Biopsy". The purpose of this study is to evaluate the efficacy, safety, and adequacy of EUS-guided liver biopsy in patients undergoing EUS-guided liver biopsy at Methodist Dallas Medical Center (MDMC).
What is the current status of trial NCT04055870?
This trial is currently completed. The enrollment target is 24 participants. The study started on 2017-08-21. Estimated completion is 2020-10-30.
What interventions are being tested in trial NCT04055870?
The interventions under investigation include: EUS-guided liver biopsy at MDMC (PROCEDURE).
Who is sponsoring clinical trial NCT04055870?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI